This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytos Biotechnology Announces Full Year 2012 Financial Results

The gross cash burn for operating activities decreased from CHF 1.54 million in average per month in 2011 to CHF 1.1 million in average per month in 2012.

    Financial summary (IFRS, consolidated)
    (in CHF million)                               Results 2012         Results 2011
    Revenue                                               1.1                  1.6
    Net operating costs                                 (14.6)               (21.3)
    Operating loss                                      (13.5)               (19.7)
    Net loss                                             (9.2)               (18.8)
    Net loss per share (in CHF)                         (0.57)               (3.56)

    (in CHF million)                          December 31, 2012    December 31, 2011
    Cash, cash equivalents, financial assets             28.7                 28.8
     & trade and other receivables
    Full-time equivalents (number)                         21                   36

The full financial statements can be found on .

Full year statutory financial figures 2012:

Financial summary (statutory)

    (in CHF million)         Results 2012    Results 2011
    Revenue                         1.1             1.6
    Total operating expenses      (20.6)          (51.3)
    Operating loss                (19.5)          (49.8)
    Other income                    6.5             6.2
    Net loss                      (15.7)          (41.3)
    (in CHF million)    December 31, 2012    December 31, 2011
    Total assets                   54.6            46.7
    Total liabilities              37.3            42.1
    Shareholder's equity           17.3             4.6

The full financial statements can be found on .

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs